<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03522792</url>
  </required_header>
  <id_info>
    <org_study_id>Neurotensin BMI/HH 2017 UCPH</org_study_id>
    <nct_id>NCT03522792</nct_id>
  </id_info>
  <brief_title>Neurotensin - an Important Regulator of Appetite in Humans?</brief_title>
  <acronym>NIRAH</acronym>
  <official_title>The Effect of Neurotensin on Appetite, Food Intake, Blood Glucose Regulation, Hormone Secretion, and the Degradation of Neurotensin in Vivo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen University Hospital, Hvidovre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurotensin (NT) is a gut peptide released postprandially from the small intestine. It is
      known to exert a range of enterogastrone effects and in animal models it reduces food intake
      when administered by parenteral routes.

      This study investigates whether the anorexic effects of NT suggested by animal studies can be
      translated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will be studied on multiple occasions (5 days) in a randomised and double blinded fashion. One day will serve as an acclimatization day.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants will not be informed of the nature of the infusion they are administered on any of the study days. The investigator will be provided with an infusion (either isotonic saline with HSA or isotonic salin with HSA + neurotensin) prepared by a designated colleague</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ad libitum food intake (ad libitum days)</measure>
    <time_frame>60 min</time_frame>
    <description>Neurotensin (NT) and saline will be infused on two occasions in random order, double blinded. After 1h of infusion an ad libitum meal will be served. When the meal is completed food intake will be determined by weighing the leftovers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ad libitum food intake (liquid meal + ad libitum days)</measure>
    <time_frame>240 min</time_frame>
    <description>Neurotensin (NT) and saline will be infused on two occasions in random order, double blinded. 1h into the infusions a standardized liquid mixed meal will be ingested. After another 180 min an ad libitum meal will be served. When the meal is completed food intake will be determined by weighing the leftovers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appetite and gastrointestinal sensations (ad libitum days)</measure>
    <time_frame>-60, -15, 15, 30, 60, 90, 120 min</time_frame>
    <description>Using visual analogue scales (VAS) the effect of infusions and meals will be documented.
Ad libitum meals will also be evaluated using VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite and gastrointestinal sensations (liquid meal + ad libitum days)</measure>
    <time_frame>-60, -15, 15, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>Using visual analogue scales (VAS) the effect of infusions and meals will be documented.
Ad libitum meals will also be evaluated using VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose (ad libitum days)</measure>
    <time_frame>-60, -30, -15, -1, 0- , 15, 30, 45, 60, 75, 90, 105, 120 min</time_frame>
    <description>Bed-side measurements of plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose (liquid meal + ad libitum days)</measure>
    <time_frame>-60, -30, -15, -1, 0- , 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 180, 240 min</time_frame>
    <description>Bed-side measurements of plasma glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotensin (ad libitum days)</measure>
    <time_frame>-60, -30, -15, -1, 0- , 15, 30, 45, 60, 75, 90, 105, 120 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotensin (liquid meal + ad libitum days)</measure>
    <time_frame>-60, -30, -15, -1, 0- , 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 180, 240 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin (liquid meal + ad libitum days)</measure>
    <time_frame>-60, -15, 15, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>Serum analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bile acids (ad libitum days)</measure>
    <time_frame>-60, -30, -15, -1, 0- , 15, 30, 45, 60, 75, 90, 105, 120 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bile acids (liquid meal + ad libitum days)</measure>
    <time_frame>-60, -15, 15, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin (ad libitum days)</measure>
    <time_frame>-60, -30, -15, -1, 0- , 15, 30, 45, 60, 75, 90, 105, 120 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin (liquid meal + ad libitum days)</measure>
    <time_frame>-60, -15, 15, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like peptide-1 (GLP-1) (ad libitum days)</measure>
    <time_frame>-60, -30, -15, -1, 0- , 15, 30, 45, 60, 75, 90, 105, 120 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like peptide-1 (GLP-1) (liquid meal + ad libitum days)</measure>
    <time_frame>-60, -15, 15, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose-dependent insulinotropic polypeptide (GIP) (liquid meal + ad libitum days)</measure>
    <time_frame>-60, -15, 15, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peptide YY (PYY) (liquid meal + ad libitum days)</measure>
    <time_frame>-60, -15, 15, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol (liquid meal + ad libitum days)</measure>
    <time_frame>-60, -15, 15, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>Serum analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic polypeptide (PP) (liquid meal + ad libitum days)</measure>
    <time_frame>-60, -15, 15, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic polypeptide (PP) (ad libitum days)</measure>
    <time_frame>-60, -30, -15, -1, 0- , 15, 30, 45, 60, 75, 90, 105, 120 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholecystokinin (CCK) (ad libitum days)</measure>
    <time_frame>-60, -30, -15, -1, 0- , 15, 30, 45, 60, 75, 90, 105, 120 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholecystokinin (CCK) (liquid meal + ad libitum days)</measure>
    <time_frame>-60, -15, 15, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>Plasma analysis</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Physiology - Regulation of Appetite and Food Intake</condition>
  <arm_group>
    <arm_group_label>Saline + ad libitum meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This will serve as the placebo / control day for the NT + ad libitum meal study day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NT + ad libitum meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neurotensin (NT) infusion followed by an ad libitum meal to study the effect of NT on ad libitum food intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline + liquid meal + ad libitum meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This will serve as the placebo / control day for the NT + standardized liquid mixed meal + ad libitum meal study day. Investigating the effect of NT on the second meal effect.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NT + liquid meal + ad libitum meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NT infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This study day aims to study the effect of NT on the second meal effect.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurotensin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acclimatization day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurotensin</intervention_name>
    <description>Intravenous infusion of neurotensin</description>
    <arm_group_label>NT + ad libitum meal</arm_group_label>
    <arm_group_label>NT + liquid meal + ad libitum meal</arm_group_label>
    <arm_group_label>Neurotensin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intravenous infusion of saline</description>
    <arm_group_label>Saline + ad libitum meal</arm_group_label>
    <arm_group_label>Saline + liquid meal + ad libitum meal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ad libitum meal</intervention_name>
    <description>Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.</description>
    <arm_group_label>Saline + ad libitum meal</arm_group_label>
    <arm_group_label>NT + ad libitum meal</arm_group_label>
    <arm_group_label>Saline + liquid meal + ad libitum meal</arm_group_label>
    <arm_group_label>NT + liquid meal + ad libitum meal</arm_group_label>
    <arm_group_label>Neurotensin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Liquid meal</intervention_name>
    <description>A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release</description>
    <arm_group_label>Saline + liquid meal + ad libitum meal</arm_group_label>
    <arm_group_label>NT + liquid meal + ad libitum meal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age = or above 18 years

          -  normal haemoglobin levels

          -  male

          -  informed consent

        Exclusion Criteria:

          -  Diabetes mellitus (fasting plasma glucose or HbA1c)

          -  Familiy history of diabetes mellitus

          -  Intestinal disease (incl e.g. inflammatory bowel disease and malabsorbtion)

          -  Family history of inflammatory bowel disease

          -  Previous intestinal resection

          -  Body mass index (BMI) over 25 kg/m2

          -  Smoker

          -  Nephropathy (S-creatinine&gt; 130 μM)

          -  Liver disease (ALAT and/or ASAT &gt; 2 × upper normal limit)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <state>Capital</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Veedfald, MD</last_name>
      <phone>+45 41 10 25 95</phone>
      <email>veedfald@sund.ku.dk</email>
    </contact>
    <contact_backup>
      <last_name>Steen Madsbad, Dr.Med.Sci</last_name>
      <email>sten.madsbad@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Simon Veedfald</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>food intake</keyword>
  <keyword>appetite</keyword>
  <keyword>obesity treatment</keyword>
  <keyword>neurotensin</keyword>
  <keyword>gastrointestinal</keyword>
  <keyword>peptide</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

